

=> d his

(FILE 'HOME' ENTERED AT 17:35:30 ON 07 NOV 2005)

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2, ...' ENTERED AT 17:35:39 ON 07 NOV 2005

L1 77699 S CYTOCHROME AND (FLAG OR TAG? OR EPITOPE)  
L2 6622 S L1 AND (FUSION OR FUSED OR CHIMER?)  
L3 1443 S L2 AND FLAG  
L4 585 S L3 AND CYTOMET?  
L5 585 S L4 AND ANTIBOD?  
L6 556 DUP REM L5 (29 DUPLICATES REMOVED)  
L7 10 S L6 AND (CYTOCHROME (P) FLAG)  
L8 546 S L6 AND FLUORESC?  
L9 7 S L8 AND (FAR (W) WESTERN)

---

=> s cytochrome and (flag or tag? or epitope)

29 FILES SEARCHED...

60 FILES SEARCHED...

L1 77699 CYTOCHROME AND (FLAG OR TAG? OR EPITOPE)

=> s l1 and (fusion or fused or chimera?)

36 FILES SEARCHED...

L2 6622 L1 AND (FUSION OR FUSED OR CHIMER?)

=> s l2 and flag

65 FILES SEARCHED...

L3 1443 L2 AND FLAG

=> s l3 and cytomet?

52 FILES SEARCHED...

L4 585 L3 AND CYTOMET?

=> s l4 and antibod?

27 FILES SEARCHED...

67 FILES SEARCHED...

L5 585 L4 AND ANTIBOD?

=> dup rem

ENTER L# LIST OR (END):15

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE, DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, PS, RDISCLOSURE, SYNTHLINE'.  
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

PROCESSING COMPLETED FOR L5

L6 556 DUP REM L5 (29 DUPLICATES REMOVED)

=> s l6 and (cytochrome (p) flag)

60 FILES SEARCHED...

65 FILES SEARCHED...

L7 10 L6 AND (CYTOCHROME (P) FLAG)

=> d l7 1-10 ibib abs

L7 ANSWER 1 OF 10 IFIPAT COPYRIGHT 2005 IFI on STN

AN 10565064 IFIPAT;IFIUDB;IFICDB

TITLE: INDUCTION OF APOPTOSIS AND CELL GROWTH INHIBITION BY

PROTEIN 4.33; COMPRISES NUCLEOTIDE SEQUENCES CODING  
INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 AND  
RECEPTORS FOR DIAGNOSIS, PREVENTION AND TREATMENT OF  
CANCER; ANTITUMOR/ANTICARCINOGENIC AGENTS

INVENTOR(S): Ingermann; Angela Renae, Portland, OR, US  
Oh; Youngman, Beaverton, OR, US  
Rosenfeld; Ron, Tualatin, OR, US  
PATENT ASSIGNEE(S): Unassigned  
PATENT ASSIGNEE PROBABLE: Oregon Health Sciences University (Probable)  
AGENT: DAVIS WRIGHT TREMAINE, LLP, 2600 CENTURY SQUARE, 1501  
FOURTH AVENUE, SEATTLE, WA, 98101-1688, US

	NUMBER	PK	DATE
PATENT INFORMATION:	US 2004072285	A1	20040415
APPLICATION INFORMATION:	US 2003-276491		20030220
	WO 2001-US16437		20010517
			20030220 PCT 371 date
			20030220 PCT 102(e) date
FAMILY INFORMATION:	US 2004072285		20040415
DOCUMENT TYPE:	Utility		
	Patent Application - First Publication		
FILE SEGMENT:	CHEMICAL		
	APPLICATION		

GOVERNMENT INTEREST:

(0001) This work was supported by Department of Defense grant 1796-1-6304 and 17-97-1-7204. The United States has certain rights in this invention, pursuant to 35 U.S.C. section 202(c) (6).

NUMBER OF CLAIMS: 54 30 Figure(s).  
DESCRIPTION OF FIGURES:

AB There is disclosed an isolated cDNA sequence (SEQ ID NO:1) encoding a P4.33 polypeptide and comprising a coding region (SEQ ID NO:2) of the sequence described in SEQ ID NO:1, or a sequence having at least 90% homology with the coding region of SEQ ID NO:1. The P4.33 polypeptide functions as a specific cell surface receptor for IGFBP-3, and undergoes nuclear translocation in combination with IGFBP-3. IGFBP-3 and P4.33 (IGFBP-3R) cooperatively suppress DNA synthesis and cell growth, and induce caspase activation and apoptosis in cancer cells, indicating that P4.33 is an important mediator of IGFBP-3 independent growth inhibitory actions of IGFBP-3. The P4.33:IGFBP-3 system of the present invention can be used, inter alia, in screening and diagnostic assays, and for therapeutic methods for cancer treatment and tumor suppression.

L7 ANSWER 2 OF 10 USPTFULL on STN

ACCESSION NUMBER: 2005:274549 USPTFULL  
TITLE: NOD2 nucleic acids and proteins  
INVENTOR(S): Nunez, Gabriel, Ann Arbor, MI, UNITED STATES  
Inohara, Naohiro, Ann Arbor, MI, UNITED STATES  
Ogura, Yasunori, Ann Arbor, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005239105	A1	20051027
APPLICATION INFO.:	US 2004-984710	A1	20041109 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-14269, filed on 26 Oct 2001, GRANTED, Pat. No. US 6835815		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-244289P	20001030 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: MEDLEN & CARROLL, LLP, 101 Howard Street, Suite 350,  
San Francisco, CA, 94105, US

NUMBER OF CLAIMS: 14  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 21 Drawing Page(s)  
LINE COUNT: 5423

AB The present invention relates to intracellular signalling molecules, in particular the Nod2 protein and nucleic acids encoding the Nod2 protein. The present invention provides isolated nucleotide sequence encoding Nod2, isolated Nod2 peptides, **antibodies** that specifically bind Nod2, methods for the detection of Nod2, and methods for screening compounds for the ability to alter Nod2 associated signal transduction.

L7 ANSWER 3 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2004:221336 USPATFULL  
TITLE: Compositions and methods for cleaving IAP  
INVENTOR(S): Du, Chunying, Leawood, KS, UNITED STATES  
Yang, Qiheng, Kansas City, KS, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004171105	A1	20040902
	US 2005233411	A9	20051020
APPLICATION INFO.:	US 2003-730476	A1	20031208 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-445508P	20030207 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	POLSINELLI SHALTON WELTE SUELTHAUS P.C., 700 W. 47TH STREET, SUITE 1000, KANSAS CITY, MO, 64112-1802	
NUMBER OF CLAIMS:	86	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	25 Drawing Page(s)	
LINE COUNT:	4866	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions and methods for making and using Omi-related and IAP-cleaving nucleotide sequences, mutant nucleotide sequences, and polypeptide sequences expressed therefrom, including both biologically active and inactive molecules. The present invention relates to cleaving IAP using an Omi polypeptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2004:120543 USPATFULL  
TITLE: Methods of modulating mitochondrial NAD-dependent deacetylase  
INVENTOR(S): Verdin, Eric M., San Francisco, CA, UNITED STATES  
North, Brian J., San Francisco, CA, UNITED STATES  
Schwer, Bjoern, San Francisco, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004091953	A1	20040513
APPLICATION INFO.:	US 2003-444633	A1	20030522 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-383069P	20020523 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD,  
SUITE 200, MENLO PARK, CA, 94025

NUMBER OF CLAIMS: 13

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 9 Drawing Page(s)

LINE COUNT: 2206

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods for identifying agents that modulate a level or an activity of a mitochondrial NAD-dependent deacetylase polypeptide, as well as agents identified by the methods. The invention further provides methods of modulating mitochondrial NAD-dependent deacetylase activity in a cell. The invention further provides methods of modulating mitochondrial function by modulating the activity of mitochondrial NAD-dependent deacetylase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2003:289108 USPATFULL

TITLE: NIP3 family of proteins

INVENTOR(S): Greenberg, Arnold H., Winnipeg, CANADA  
Geiger, Jonathan D., Winnipeg, CANADA  
Kirshenbaum, Lorrie A., Winnipeg, CANADA  
Hellner, Faye, Winnipeg, CANADA LR

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003203867	A1	20031030
APPLICATION INFO.:	US 2002-290461	A1	20021108 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US21043, filed on 29 Jun 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-215643P	20000630 (60)
	US 2000-219554P	20000720 (60)
	US 2001-348135P	20011109 (60)
	US 2001-344196P	20011228 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: BERESKIN AND PARR, SCOTIA PLAZA, 40 KING STREET  
WEST-SUITE 4000 BOX 401, TORONTO, ON, M5H 3Y2

NUMBER OF CLAIMS: 35

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 35 Drawing Page(s)

LINE COUNT: 3653

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions for modulating necrosis and for treating neurological and cardiovascular diseases are described. The inventors have shown that BNIP3 is involved in cell necrosis and cell death involved in cardiovascular and neurological diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2003:251033 USPATFULL

TITLE: Methods for identifying modulators of apoptosis

INVENTOR(S): Reed, John C., Rancho Santa Fe, CA, UNITED STATES  
Guo, Bin, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175819	A1	20030918
APPLICATION INFO.:	US 2002-306878	A1	20021127 (10)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2001-334149P	20011128 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CAMPBELL & FLORES LLP, 4370 LA JOLLA VILLAGE DRIVE, 7TH FLOOR, SAN DIEGO, CA, 92122	
NUMBER OF CLAIMS:	77	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	3438	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a method of identifying an effective compound that modulates the binding of Humanin to Bax or Bid. The invention also provides a method of identifying an effective compound that modulates an activity of Bax or Bid. In addition, the invention provides a method of identifying a Humanin-like compound that binds to Bax or Bid or modulates an activity of Bax or Bid, or inhibits the apoptotic activity of Bax or Bid. The invention further provides an isolated polypeptide containing a mitochondrial-derived form of Humanin (SEQ ID NO:3) or a functional fragment thereof where the fragment contains the methionine at position 16 of SEQ ID NO:3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2003:250976 USPATFULL  
 TITLE: Modulators on Nod2 signaling  
 INVENTOR(S): Nunez, Gabriel, Ann Arbor, MI, UNITED STATES  
 Inohara, Naohiro, Ann Arbor, MI, UNITED STATES  
 Ogura, Yasunori, Ann Arbor, MI, UNITED STATES  
 PATENT ASSIGNEE(S): The Regents of the University of Michigan, Ann Arbor, MI (U.S. corporation)

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 2003175762	A1	20030918
APPLICATION INFO.:	US 2002-314506	A1	20021209 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-14269, filed on 26 Oct 2001, PENDING		

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2000-244289P	20001030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	33 Drawing Page(s)	
LINE COUNT:	4803	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to intracellular signaling molecules, in particular the Nod2 protein and nucleic acids encoding the Nod2 protein. The present invention provides methods of identifying modulators of Nod2 signaling. In particular, the present invention additionally provides methods of screening immune modulators such as adjuvants using Nod2. The present invention further provides methods of altering Nod2 signaling.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2002:343890 USPATFULL  
 TITLE: Nod2 nucleic acids and proteins

INVENTOR(S): Nunez, Gabriel, Ann Arbor, MI, UNITED STATES  
Inohara, Naohiro, Ann Arbor, MI, UNITED STATES  
Ogura, Yasunori, Ann Arbor, MI, UNITED STATES  
Cho, Judy, Chicago, IL, UNITED STATES  
Nicolae, Dan L., Chicago, IL, UNITED STATES  
Bonen, Denise, Chicago, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002197616	A1	20021226
	US 6858391	B2	20050222
APPLICATION INFO.:	US 2001-2974	A1	20011026 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-244266P	20001030 (60)
	US 2001-286316P	20010425 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	David A. Casimir, MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	49 Drawing Page(s)	
LINE COUNT:	8372	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to intracellular signalling molecules, in particular the Nod2 protein and nucleic acids encoding the Nod2 protein. The present invention provides isolated nucleotide sequence encoding Nod2, isolated Nod2 peptides, **antibodies** that specifically bind Nod2, methods for the detection of Nod2, and methods for screening compounds for the ability to alter Nod2 associated signal transduction. The present invention also provides Nod2 variant alleles. The present invention further provides methods of identifying individuals at increased risk of developing Crohn's disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2002:235484 USPATFULL  
TITLE: Nod2 nucleic acids and proteins  
INVENTOR(S): Nunez, Gabriel, Ann Arbor, MI, UNITED STATES  
Inohara, Naohiro, Ann Arbor, MI, UNITED STATES  
Ogura, Yasunori, Ann Arbor, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002127673	A1	20020912
	US 6835815	B2	20041228
APPLICATION INFO.:	US 2001-14269	A1	20011026 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-244289P	20001030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	David A. Casimir, MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	21 Drawing Page(s)	
LINE COUNT:	5519	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to intracellular signalling molecules, in particular the Nod2 protein and nucleic acids encoding the Nod2 protein.

The present invention provides isolated nucleotide sequence encoding Nod2, isolated Nod2 peptides, **antibodies** that specifically bind Nod2, methods for the detection of Nod2, and methods for screening compounds for the ability to alter Nod2 associated signal transduction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2002:206158 USPATFULL

TITLE: Novel polypeptides, modulatory agents therefor and methods of using them

INVENTOR(S): Verhagen, Anne Marie, Northcote, AUSTRALIA  
Ekert, Paul Gerald, Elsternwick, AUSTRALIA  
Vaux, David Lawrence, Fairfield, AUSTRALIA

PATENT ASSIGNEE(S): The Walter and Eliza Hall Institute of Medical Research  
of Royal Parade (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002110851	A1	20020815
APPLICATION INFO.:	US 2001-798116	A1	20010302 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	AU 2000-5995	20000302
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P., ONE COMMERCE SQUARE, 2005 MARKET STREET, SUITE 2200, PHILADELPHIA, PA, 19103	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	3678	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pro-apoptotic polypeptide, designated DIABLO, is disclosed which inhibits the activity of IAPs, including animal and viral IAPs. Also disclosed are methods of using DIABLO polypeptides and DIABLO-encoding polynucleotides to screen for modulatory agents that modulate the level and/or functional activity of DIABLO, as well as methods for detecting cell death or apoptosis, and for diagnosis of conditions relating to the expression or activation of DIABLO. The invention also discloses compositions for treating and/or preventing such DIABLO-related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 16 and fluoresc?

26 FILES SEARCHED...

56 FILES SEARCHED...

65 FILES SEARCHED...

L8 546 L6 AND FLUORESC?

=> s 18 and (far (w) western)

47 FILES SEARCHED...

L9 7 L8 AND (FAR (W) WESTERN)

=> d 19 1-7 ibib abs

L9 ANSWER 1 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2005:177842 USPATFULL

TITLE: Targeted drug delivery using EphA2 or EphA4 binding moieties

INVENTOR(S): Kinch, Michael S., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005153923	A1	20050714	
APPLICATION INFO.:	US 2004-4794	A1	20041203	(11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-527396P	20031204 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US	
NUMBER OF CLAIMS:	47	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	31 Drawing Page(s)	
LINE COUNT:	7929	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and compositions designed for the treatment, management, or prevention of a hyperproliferative cell disease, particularly cancer. The methods of the invention comprise the administration of an effective amount of a composition that targets cells expressing an Eph family receptor tyrosine kinase, such as EphA2 or EphA4, for the treatment, management, or prevention of hyperproliferative diseases, particularly cancer. In one embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety attached to a delivery vehicle, and one or more therapeutic or prophylactic agents that treat or prevent a hyperproliferative disease, where the therapeutic or prophylactic agents are operatively associated with the delivery vehicle. In another embodiment, the method of the invention comprises administering to a subject a composition comprising a nucleic acid comprising a nucleotide sequence encoding an EphA2 or EphA4 targeting moiety and a therapeutic or prophylactic agent that treats or prevents a hyperproliferative disease. In yet another embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety and a nucleic acid comprising a nucleotide sequence encoding an agent that treats or prevents a hyperproliferative disease, where the nucleic acid is operatively associated with the delivery vehicle. Pharmaceutical compositions are also provided by the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2005:170846 USPATFULL

TITLE: EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders

INVENTOR(S): Kinch, Michael S., Laytonsville, MD, UNITED STATES

PATENT ASSIGNEE(S): MedImmune, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005147593	A1	20050707	
APPLICATION INFO.:	US 2004-4795	A1	20041203	(11)

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2003-US16269	20030522
	US 2003-527154P	20031204 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US	
NUMBER OF CLAIMS:	45	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	32 Drawing Page(s)	
LINE COUNT:	8605	



CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and compositions designed for treatment, management, or prevention of a hyperproliferative cell disease, particular cancer. The methods of the invention comprise the administration of an effective amount of a composition that targets cells expressing low molecular weight protein tyrosine kinase ("LMW-PTP") in particular using moieties that bind an Eph family receptor tyrosine kinase, such as EphA2 or EphA4, and inhibits or reduces LMW-PTP expression and/or activity. In one embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety attached to a delivery vehicle, and one or more agents that inhibit LMW-PTP expression and/or activity operatively associated with the delivery vehicle. In another embodiment, the method of the invention comprises administering to a subject a composition comprising a nucleic acid comprising a nucleotide sequence encoding an EphA2 or EphA4 targeting moiety and an agent that inhibits or reduces LMW-PTP expression and/or activity. In yet another embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety and a nucleic acid comprising a nucleotide sequence encoding an agent that inhibits or reduces LMW-PTP expression and/or activity, where the nucleic acid is operatively associated with the delivery vehicle. Pharmaceutical compositions are also provided by the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2005:143828 USPATFULL

TITLE: Lipoparticles comprising proteins, methods of making, and using the same

INVENTOR(S): Doranz, Benjamin J., Narberth, PA, UNITED STATES  
Willis, Sharon, Wayne, PA, UNITED STATES  
Ross, Eric, Philadelphia, PA, UNITED STATES  
Greene, Tiffani Anne, Cherry Hill, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005123563	A1	20050609
APPLICATION INFO.:	US 2004-901399	A1	20040728 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-491477P	20030730 (60)
	US 2003-491633P	20030730 (60)
	US 2003-498755P	20030829 (60)
	US 2003-502478P	20030912 (60)
	US 2003-509677P	20031007 (60)
	US 2003-509608P	20031007 (60)
	US 2003-509575P	20031007 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: COZEN O'CONNOR, P.C., 1900 MARKET STREET, PHILADELPHIA, PA, 19103-3508, US

NUMBER OF CLAIMS: 147

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 33 Drawing Page(s)

LINE COUNT: 12584

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to lipoparticles. The invention also relates to producing lipoparticles. The invention further relates to lipoparticles comprising a viral structural protein. The invention further relates to a lipoparticle comprising a membrane protein, and the lipoparticle can be attached to a sensor surface. The invention further relates to methods of producing and using the lipoparticle to, inter

alia, assess protein binding interactions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2005:112372 USPATFULL  
TITLE: Full-length human cDNAs encoding potentially secreted proteins  
INVENTOR(S): Dumas Milne Edwards, Jean-Baptiste, Paris, FRANCE  
Bougueleret, Lydie, Petit Lancy, SWITZERLAND  
Jobert, Severin, Paris, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005096458	A1	20050505
APPLICATION INFO.:	US 2003-643836	A1	20030819 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-731872, filed on 7 Dec 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-169629P	19991208 (60)
	US 2000-187470P	20000306 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO BOX 142950, GAINESVILLE, FL, 32614-2950, US	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	28075	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2004:227372 USPATFULL  
TITLE: Novel Goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders  
INVENTOR(S): Saus, Juan, Valencia, SPAIN  
Revert, Fernando, Valencia, SPAIN  
Revert-Ros, Francisco, Valencia, SPAIN  
PATENT ASSIGNEE(S): Dr. Juan Saus (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004175758	A1	20040909
APPLICATION INFO.:	US 2004-772656	A1	20040205 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-445043P	20030205 (60)
	US 2003-445003P	20030205 (60)
	US 2003-445004P	20030205 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, 300 S. WACKER	

DRIVE, 32ND FLOOR, CHICAGO, IL, 60606

NUMBER OF CLAIMS: 33  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 14 Drawing Page(s)  
LINE COUNT: 7940

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel isoforms of the Goodpasture antigen binding protein (GPBP), and related reagents, and also provides methods for isolating and detecting such novel GPBP isoforms. The invention further provides methods identifying compounds to treat one or more of an autoimmune condition and a protein deposit-mediated disorder, as well as novel compounds and methods for treating such conditions and/or disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2003:219631 USPATFULL  
TITLE: Full-length human cDNAs encoding potentially secreted proteins  
INVENTOR(S): Dumas Milne Edwards, Jean-Baptiste, Paris, FRANCE  
Bougueleret, Lydie, Petit Lancy, SWITZERLAND  
Jobert, Severin, Paris, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003152921	A1	20030814
APPLICATION INFO.:	US 2001-876997	A1	20010608 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-731872, filed on 7 Dec 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-169629P	19991208 (60)
	US 2000-187470P	20000306 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Frank C. Eisenschenk, Ph.D., SALIWANCHIK, LLOYD & SALIWANCHIK, 2421 N.W. 41 STREET, SUITE A-1, GAINESVILLE, FL, 32606-6669	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	27600	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2002:191539 USPATFULL  
TITLE: Full-length human cDNAs encoding potentially secreted proteins  
INVENTOR(S): Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE  
Bougueleret, Lydie, Petit Lancy, SWITZERLAND  
Jobert, Severin, Paris, FRANCE

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2002102604 A1 20020801  
APPLICATION INFO.: US 2000-731872 A1 20001207 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-169629P	19991208 (60)
	US 2000-187470P	20000306 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	John Lucas, Ph.D., J.D., Genset Corporation, 10665 Sorrento Valley Road, San Diego, CA, 92121-1609	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	28061	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> logoff y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	220.40	220.61

STN INTERNATIONAL LOGOFF AT 18:12:32 ON 07 NOV 2005